J. Jefferson Smith - Jan 20, 2024 Form 4 Insider Report for PRECISION BIOSCIENCES INC (DTIL)

Role
Chief Research Officer
Signature
/s/ Dario Scimeca, Attorney-in-Fact for J. Jefferson Smith
Stock symbol
DTIL
Transactions as of
Jan 20, 2024
Transactions value $
-$10,360
Form type
4
Date filed
1/23/2024, 07:11 PM
Previous filing
Sep 5, 2023
Next filing
May 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DTIL Common Stock Options Exercise +75K +3.87% 2.02M Jan 20, 2024 Direct F1, F2
transaction DTIL Common Stock Sale -$10.4K -28K -1.39% $0.37 1.99M Jan 23, 2024 Direct F3, F4
holding DTIL Common Stock 238K Jan 20, 2024 By Charitable Remainder Unitrust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DTIL Restricted Stock Units Options Exercise $0 -75K -33.34% $0.00 150K Jan 20, 2024 Common Stock 75K Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on January 20, 2024.
F2 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share.
F3 The transaction was a sell-to-cover, with shares sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The reporting person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.35495 to $0.37790. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.
F5 On January 20, 2023 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.